COMMUNIQUÉS West-GlobeNewswire

MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
21/05/2018
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO 2 and NYHA Classification Improvements Expected to Initiate in Second Quarter 2018; Topline [...]
Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
21/05/2018
- Lefamulin met all FDA and EMA primary endpoints and was shown to be generally well tolerated - - Company plans to file a New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2018 [...]
Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
21/05/2018
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly [...]
AxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the Board
21/05/2018
ALACHUA, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that its Board of Directors [...]
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
21/05/2018
– FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring fibrils – – [...]
Microbot Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt
21/05/2018
Data from Pre-Clinical Study Indicates the Self-Cleaning Shunt has the Potential to be a Viable Technology for Preventing Occlusion in Shunts Used to Treat Hydrocephalus HINGHAM, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- [...]
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
21/05/2018
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference call today at 8:30 a. [...]
BriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
21/05/2018
BERKELEY, Calif. and VANCOUVER, British Columbia, May 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT ) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a [...]
Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
21/05/2018
– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – WATERTOWN, Mass., May 21 [...]
Terveystalo Plc: Managers' Transactions
21/05/2018
TERVEYSTALO PLC MANAGERS' TRANSACTIONS 21 May 2018 at 12:35 EEST ____________________________________________ Person subject to the notification requirement Name: Keskinäinen työeläkevakuutusyhtiö Varma Position: [...]
NovoEight® maintains potency when stored at 40ºC offering people with haemophilia A increased flexibility in their daily lives
21/05/2018
Glasgow, UK, 21 May 2018 - A new long term stability study has shown that haemophilia A treatment NovoEight ® (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC. 1 The results were [...]
Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
21/05/2018
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned, US-based subsidiary, [...]
Terveystalo Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act (Rettig)
21/05/2018
TERVEYSTALO PLC STOCK EXCHANGE RELEASE 21 May 2018 at 9.20 a.m. EEST Terveystalo Plc ("Terveystalo" or the "Company") has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets [...]
Terveystalo Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act (EQT)
21/05/2018
TERVEYSTALO PLC STOCK EXCHANGE RELEASE 21 May 2018 at 9.10 a.m. EEST Terveystalo Plc ("Terveystalo" or the "Company") has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets [...]
Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial
21/05/2018
Press Release 21 May 2018 Immunicum AB (publ) Announces End of Enrollment in Phase I/II GIST Clinical Trial Immunicum AB (publ; IMMU.ST) today announced that the sixth and last patient has been enrolled in the first [...]
Shire plc : Rule 2.9 Announcement
21/05/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 21 May 2018 Shire [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
21/05/2018
REGULATED INFORMATION GHENT, Belgium, 21 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
20/05/2018
Mechelen, Belgium; 20 May 2018; 20.30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces publication milestones on GLPG1690 in idiopathic pulmonary fibrosis (IPF). In addition to presenting three abstracts on [...]
Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting
19/05/2018
- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD - - Company Continues to Advance Gene Therapy Portfolio - CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( [...]

Pages